丽丰(01125.HK)获两股东增持至持股逾10% 公众持股量跌至低於上市规定
丽丰控股(01125.HK)公布,今年9月16日,余卓儿和余少玉共同购买16.8万股公司股本中每股面值5元之普通股,占公司全部已发行股份约0.051%。紧随购买完成後,余氏两人合共持有3,286.5万股股份,占公司全部已发行股份约10.04%。
由於余氏两人已成为公司之主要股东,按照联交所上市规则,余氏两人已成为公司之核心关连人士及余氏持有之股份将不计入公司的公众持股量。计及余氏两人与公司其他核心关连人士之持股,公司之公众持股量约为18.84%,跌至低於上市规则规定公司全部已发行股份之25%须由公众人士持有之水平。
公司指,现正考虑采取不同的措施恢复公司的公众持股量至按照上市规则的最低规定百份比。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.